Literature DB >> 18644693

MicroRNAs: key players in carcinogenesis and novel therapeutic targets.

A H F Mirnezami1, K Pickard, L Zhang, J N Primrose, G Packham.   

Abstract

MicroRNAs (miRNAs) represent a recently uncovered class of small and endogenous non-coding RNAs. MiRNA function is critical to normal cellular processes such as differentiation and apoptosis, and recent studies have demonstrated that deregulated miRNA expression contributes to the malignant phenotype. The purpose of this review is to summarise these findings in relation to the most common human malignancies, and to analyse the clinical and therapeutic opportunities they provide.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18644693     DOI: 10.1016/j.ejso.2008.06.006

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  54 in total

1.  MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma.

Authors:  Kai Sun; Wei Wang; Jun-jie Zeng; Cheng-tang Wu; Shang-tong Lei; Guo-xin Li
Journal:  Acta Pharmacol Sin       Date:  2011-01-31       Impact factor: 6.150

2.  In Vitro Anti-hepatoma Activities of Notoginsenoside R1 Through Downregulation of Tumor Promoter miR-21.

Authors:  Yuan Li; Zhong Li; Yunhao Jia; Bo Ding; Jinsong Yu
Journal:  Dig Dis Sci       Date:  2019-09-26       Impact factor: 3.199

Review 3.  Biomarkers in Spinal Cord Injury: from Prognosis to Treatment.

Authors:  Leonardo Fonseca Rodrigues; Vivaldo Moura-Neto; Tania Cristina Leite de Sampaio E Spohr
Journal:  Mol Neurobiol       Date:  2018-01-06       Impact factor: 5.590

4.  MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway.

Authors:  Yang Liu; Juan Tan; Shuangyan Ou; Jun Chen; Limin Chen
Journal:  Invest New Drugs       Date:  2019-03-30       Impact factor: 3.850

5.  MicroRNAs: tools for cancer diagnostics.

Authors:  T Paranjape; F J Slack; J B Weidhaas
Journal:  Gut       Date:  2009-11       Impact factor: 23.059

6.  MiR-338-3p inhibits the proliferation and migration of gastric cancer cells by targeting ADAM17.

Authors:  Jiang-Tao Chen; Kun-Hou Yao; Long Hua; Li-Ping Zhang; Chen-Yu Wang; Jun-Jie Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  Methylation-mediated repression of potential tumor suppressor miR-203a and miR-203b contributes to esophageal squamous cell carcinoma development.

Authors:  Yibing Liu; Zhiming Dong; Jia Liang; Yanli Guo; Xin Guo; Supeng Shen; Gang Kuang; Wei Guo
Journal:  Tumour Biol       Date:  2015-11-17

Review 8.  Role of miRNAs in the progression of malignant melanoma.

Authors:  D W Mueller; A K Bosserhoff
Journal:  Br J Cancer       Date:  2009-07-28       Impact factor: 7.640

9.  MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs.

Authors:  Liqin Du; Jeoffrey J Schageman; Luc Girard; Scott M Hammond; John D Minna; Adi F Gazdar; Alexander Pertsemlidis
Journal:  J Exp Clin Cancer Res       Date:  2010-06-17

10.  miR-21: an oncomir on strike in prostate cancer.

Authors:  Marco Folini; Paolo Gandellini; Nicole Longoni; Valentina Profumo; Maurizio Callari; Marzia Pennati; Maurizio Colecchia; Rosanna Supino; Silvia Veneroni; Roberto Salvioni; Riccardo Valdagni; Maria Grazia Daidone; Nadia Zaffaroni
Journal:  Mol Cancer       Date:  2010-01-21       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.